ArticleBMC infectious diseases2024

Nirmatrelvir and ritonavir for inpatients with severe or critical COVID-19 beyond five days of symptom onset: a propensity score-matched, multicenter, retrospective cohort study.

Huan Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.